Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study
Proteinuria and anti–phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with...
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2024-05, Vol.83 (5), p.588-600.e1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 600.e1 |
|---|---|
| container_issue | 5 |
| container_start_page | 588 |
| container_title | American journal of kidney diseases |
| container_volume | 83 |
| creator | Ruggenenti, Piero Reinhard, Linda Ruggiero, Barbara Perna, Annalisa Perico, Luca Peracchi, Tobia Fidone, Diego Gennarini, Alessia Benigni, Ariela Cortinovis, Monica Hoxha, Elion Remuzzi, Giuseppe |
| description | Proteinuria and anti–phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes.
Prospective cohort study.
One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes.
Rituximab.
Complete (proteinuria |
| doi_str_mv | 10.1053/j.ajkd.2023.10.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2907196579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638623009939</els_id><sourcerecordid>2907196579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-732ece94443b6ca721c404b14602309764238db1adecf0fc6c74cafd640017bb3</originalsourceid><addsrcrecordid>eNp9kU2O1DAQhSMEYpqBC7BAXrIgjf_iJIhNqxl-pAFGDawtx64QN504YzsjsuMOHIJ7cRKc6YYlq5Kevld6VS_LHhO8Jrhgz_drtf9m1hRTloQ1JuxOtiIFZbmoWHU3W2Fa0lywSpxlD0LYY4xrJsT97IxVpCCU8lX2azNE-_vHz6vOhbFzBzuqAGhD0Q40jNF5RJAaDDph2zlEsAOgndXdrdg4YyE8Q69cr-yw2NzXwUbrhlvfzsbpu-1Vgy7a1mqlZ5So99A3Xg1uCugDjJ13o4rd_AJt0JVPOUBHewNo6zrnI_oUJzM_zO616hDg0WmeZ19eX3zevs0vP755t91c5poVIuYloyl3zTlnjdCqpERzzBvCRXoSrkvBKatMQ5QB3eJWC11yrVojOMakbBp2nj097h29u54gRNnboOFwUAOkuJLWuCS1KMo6ofSI6pQ5eGjl6NOlfpYEy6UguZdLQXIpaNFSQcn05LR_anow_yx_G0nAyyMA6cobC14GbWHQYKxPf5HG2f_t_wPWj6V7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2907196579</pqid></control><display><type>article</type><title>Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ruggenenti, Piero ; Reinhard, Linda ; Ruggiero, Barbara ; Perna, Annalisa ; Perico, Luca ; Peracchi, Tobia ; Fidone, Diego ; Gennarini, Alessia ; Benigni, Ariela ; Cortinovis, Monica ; Hoxha, Elion ; Remuzzi, Giuseppe</creator><creatorcontrib>Ruggenenti, Piero ; Reinhard, Linda ; Ruggiero, Barbara ; Perna, Annalisa ; Perico, Luca ; Peracchi, Tobia ; Fidone, Diego ; Gennarini, Alessia ; Benigni, Ariela ; Cortinovis, Monica ; Hoxha, Elion ; Remuzzi, Giuseppe</creatorcontrib><description><![CDATA[Proteinuria and anti–phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes.
Prospective cohort study.
One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes.
Rituximab.
Complete (proteinuria<0.3g/24h) or partial (proteinuria≥0.3g/24h and<3.0g/24h with>50% reduction vs basal) NS remission.
Univariable and multivariable Cox regression analyses.
All patients had anti-CysR antibodies; 62 (54.9%) were multidomain recognizers. Anti-PLA2R1 and anti-CysR antibody titers were strongly correlated at baseline (P<0.001, r=0.934), 6 months (P<0.001, r=0.964), and 12 months (P<0.001, r=0.944). During a median follow-up of 37.1 (IQR, 20.3-56.9) months, 71 patients (62.8%) achieved either complete or partial remission of their NS. Lower baseline anti-PLA2R1 (HR, 0.997 [95% CI, 0.996-0.999], P=0.002) and anti-CysR [HR, 0.996 [95% CI, 0.993-0.998], P=0.001) titers were associated with a higher probability of remission, along with female sex, lower proteinuria, and lower serum creatinine levels (P<0.05 for all comparisons). Anti-CTLD antibodies were not associated with outcomes. At 6 and 12 months, compared to baseline, anti-PLA2R1 and anti-CysR antibody titers decreased more in patients progressing to partial or complete remission than in those without remission (P<0.05 for all comparisons).
Observational design.
In PLA2R1-related MN, anti-PLA2R1 and anti-CysR antibodies similarly predict rituximab efficacy independent of PLA2R1 domain recognition. The choice between these tests should be dictated by feasibility and costs. Evaluating anti-CTLD antibodies appears unnecessary.
Primary membranous nephropathy (MN), a leading cause of nephrotic syndrome (NS) in adults, is an autoimmune disease caused by autoantibodies binding to the podocyte antigen phospholipase A2 receptor 1 (PLA2R1). We assessed whether the effects of anti-CD20 cytolytic therapy with the monoclonal antibody rituximab are associated with detection rates and levels of anti-PLA2R1 antibodies and antibodies against PLA2R1 domains such as cysteine-rich (CysR), and C-type lectin 1, 7, and 8 (CTLD1, 7, and 8), in patients with PLA2R1-related MN and persistent NS. The probability of rituximab-induced complete or partial NS remission was associated with baseline anti-PLA2R1 and anti-CysR antibody titers, but not with anti-CTLD1, 7 and 8 antibodies or multidomain recognition. Integrated evaluation of anti-PLA2R1 or anti-CysR antibodies with proteinuria and kidney function may play a role in monitoring the effects of rituximab in patients with PLA2R1-related NS and MN.
[Display omitted]]]></description><identifier>ISSN: 0272-6386</identifier><identifier>ISSN: 1523-6838</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2023.10.013</identifier><identifier>PMID: 38151224</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Autoantibodies - blood ; Autoantibodies - immunology ; Cohort Studies ; CysR ; Cysteine ; domain recognition ; Female ; Glomerulonephritis, Membranous - drug therapy ; Glomerulonephritis, Membranous - immunology ; Humans ; Immunologic Factors - therapeutic use ; Male ; membranous nephropathy ; Middle Aged ; nephrotic syndrome ; PLA2R1 ; Prospective Studies ; Proteinuria - drug therapy ; Receptors, Phospholipase A2 - immunology ; rituximab ; Rituximab - therapeutic use ; sex ; Treatment Outcome</subject><ispartof>American journal of kidney diseases, 2024-05, Vol.83 (5), p.588-600.e1</ispartof><rights>2023 National Kidney Foundation, Inc.</rights><rights>Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-732ece94443b6ca721c404b14602309764238db1adecf0fc6c74cafd640017bb3</citedby><cites>FETCH-LOGICAL-c356t-732ece94443b6ca721c404b14602309764238db1adecf0fc6c74cafd640017bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2023.10.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38151224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruggenenti, Piero</creatorcontrib><creatorcontrib>Reinhard, Linda</creatorcontrib><creatorcontrib>Ruggiero, Barbara</creatorcontrib><creatorcontrib>Perna, Annalisa</creatorcontrib><creatorcontrib>Perico, Luca</creatorcontrib><creatorcontrib>Peracchi, Tobia</creatorcontrib><creatorcontrib>Fidone, Diego</creatorcontrib><creatorcontrib>Gennarini, Alessia</creatorcontrib><creatorcontrib>Benigni, Ariela</creatorcontrib><creatorcontrib>Cortinovis, Monica</creatorcontrib><creatorcontrib>Hoxha, Elion</creatorcontrib><creatorcontrib>Remuzzi, Giuseppe</creatorcontrib><title>Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description><![CDATA[Proteinuria and anti–phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes.
Prospective cohort study.
One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes.
Rituximab.
Complete (proteinuria<0.3g/24h) or partial (proteinuria≥0.3g/24h and<3.0g/24h with>50% reduction vs basal) NS remission.
Univariable and multivariable Cox regression analyses.
All patients had anti-CysR antibodies; 62 (54.9%) were multidomain recognizers. Anti-PLA2R1 and anti-CysR antibody titers were strongly correlated at baseline (P<0.001, r=0.934), 6 months (P<0.001, r=0.964), and 12 months (P<0.001, r=0.944). During a median follow-up of 37.1 (IQR, 20.3-56.9) months, 71 patients (62.8%) achieved either complete or partial remission of their NS. Lower baseline anti-PLA2R1 (HR, 0.997 [95% CI, 0.996-0.999], P=0.002) and anti-CysR [HR, 0.996 [95% CI, 0.993-0.998], P=0.001) titers were associated with a higher probability of remission, along with female sex, lower proteinuria, and lower serum creatinine levels (P<0.05 for all comparisons). Anti-CTLD antibodies were not associated with outcomes. At 6 and 12 months, compared to baseline, anti-PLA2R1 and anti-CysR antibody titers decreased more in patients progressing to partial or complete remission than in those without remission (P<0.05 for all comparisons).
Observational design.
In PLA2R1-related MN, anti-PLA2R1 and anti-CysR antibodies similarly predict rituximab efficacy independent of PLA2R1 domain recognition. The choice between these tests should be dictated by feasibility and costs. Evaluating anti-CTLD antibodies appears unnecessary.
Primary membranous nephropathy (MN), a leading cause of nephrotic syndrome (NS) in adults, is an autoimmune disease caused by autoantibodies binding to the podocyte antigen phospholipase A2 receptor 1 (PLA2R1). We assessed whether the effects of anti-CD20 cytolytic therapy with the monoclonal antibody rituximab are associated with detection rates and levels of anti-PLA2R1 antibodies and antibodies against PLA2R1 domains such as cysteine-rich (CysR), and C-type lectin 1, 7, and 8 (CTLD1, 7, and 8), in patients with PLA2R1-related MN and persistent NS. The probability of rituximab-induced complete or partial NS remission was associated with baseline anti-PLA2R1 and anti-CysR antibody titers, but not with anti-CTLD1, 7 and 8 antibodies or multidomain recognition. Integrated evaluation of anti-PLA2R1 or anti-CysR antibodies with proteinuria and kidney function may play a role in monitoring the effects of rituximab in patients with PLA2R1-related NS and MN.
[Display omitted]]]></description><subject>Adult</subject><subject>Aged</subject><subject>Autoantibodies - blood</subject><subject>Autoantibodies - immunology</subject><subject>Cohort Studies</subject><subject>CysR</subject><subject>Cysteine</subject><subject>domain recognition</subject><subject>Female</subject><subject>Glomerulonephritis, Membranous - drug therapy</subject><subject>Glomerulonephritis, Membranous - immunology</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Male</subject><subject>membranous nephropathy</subject><subject>Middle Aged</subject><subject>nephrotic syndrome</subject><subject>PLA2R1</subject><subject>Prospective Studies</subject><subject>Proteinuria - drug therapy</subject><subject>Receptors, Phospholipase A2 - immunology</subject><subject>rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>sex</subject><subject>Treatment Outcome</subject><issn>0272-6386</issn><issn>1523-6838</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2O1DAQhSMEYpqBC7BAXrIgjf_iJIhNqxl-pAFGDawtx64QN504YzsjsuMOHIJ7cRKc6YYlq5Kevld6VS_LHhO8Jrhgz_drtf9m1hRTloQ1JuxOtiIFZbmoWHU3W2Fa0lywSpxlD0LYY4xrJsT97IxVpCCU8lX2azNE-_vHz6vOhbFzBzuqAGhD0Q40jNF5RJAaDDph2zlEsAOgndXdrdg4YyE8Q69cr-yw2NzXwUbrhlvfzsbpu-1Vgy7a1mqlZ5So99A3Xg1uCugDjJ13o4rd_AJt0JVPOUBHewNo6zrnI_oUJzM_zO616hDg0WmeZ19eX3zevs0vP755t91c5poVIuYloyl3zTlnjdCqpERzzBvCRXoSrkvBKatMQ5QB3eJWC11yrVojOMakbBp2nj097h29u54gRNnboOFwUAOkuJLWuCS1KMo6ofSI6pQ5eGjl6NOlfpYEy6UguZdLQXIpaNFSQcn05LR_anow_yx_G0nAyyMA6cobC14GbWHQYKxPf5HG2f_t_wPWj6V7</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Ruggenenti, Piero</creator><creator>Reinhard, Linda</creator><creator>Ruggiero, Barbara</creator><creator>Perna, Annalisa</creator><creator>Perico, Luca</creator><creator>Peracchi, Tobia</creator><creator>Fidone, Diego</creator><creator>Gennarini, Alessia</creator><creator>Benigni, Ariela</creator><creator>Cortinovis, Monica</creator><creator>Hoxha, Elion</creator><creator>Remuzzi, Giuseppe</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202405</creationdate><title>Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study</title><author>Ruggenenti, Piero ; Reinhard, Linda ; Ruggiero, Barbara ; Perna, Annalisa ; Perico, Luca ; Peracchi, Tobia ; Fidone, Diego ; Gennarini, Alessia ; Benigni, Ariela ; Cortinovis, Monica ; Hoxha, Elion ; Remuzzi, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-732ece94443b6ca721c404b14602309764238db1adecf0fc6c74cafd640017bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Autoantibodies - blood</topic><topic>Autoantibodies - immunology</topic><topic>Cohort Studies</topic><topic>CysR</topic><topic>Cysteine</topic><topic>domain recognition</topic><topic>Female</topic><topic>Glomerulonephritis, Membranous - drug therapy</topic><topic>Glomerulonephritis, Membranous - immunology</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Male</topic><topic>membranous nephropathy</topic><topic>Middle Aged</topic><topic>nephrotic syndrome</topic><topic>PLA2R1</topic><topic>Prospective Studies</topic><topic>Proteinuria - drug therapy</topic><topic>Receptors, Phospholipase A2 - immunology</topic><topic>rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>sex</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruggenenti, Piero</creatorcontrib><creatorcontrib>Reinhard, Linda</creatorcontrib><creatorcontrib>Ruggiero, Barbara</creatorcontrib><creatorcontrib>Perna, Annalisa</creatorcontrib><creatorcontrib>Perico, Luca</creatorcontrib><creatorcontrib>Peracchi, Tobia</creatorcontrib><creatorcontrib>Fidone, Diego</creatorcontrib><creatorcontrib>Gennarini, Alessia</creatorcontrib><creatorcontrib>Benigni, Ariela</creatorcontrib><creatorcontrib>Cortinovis, Monica</creatorcontrib><creatorcontrib>Hoxha, Elion</creatorcontrib><creatorcontrib>Remuzzi, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruggenenti, Piero</au><au>Reinhard, Linda</au><au>Ruggiero, Barbara</au><au>Perna, Annalisa</au><au>Perico, Luca</au><au>Peracchi, Tobia</au><au>Fidone, Diego</au><au>Gennarini, Alessia</au><au>Benigni, Ariela</au><au>Cortinovis, Monica</au><au>Hoxha, Elion</au><au>Remuzzi, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2024-05</date><risdate>2024</risdate><volume>83</volume><issue>5</issue><spage>588</spage><epage>600.e1</epage><pages>588-600.e1</pages><issn>0272-6386</issn><issn>1523-6838</issn><eissn>1523-6838</eissn><abstract><![CDATA[Proteinuria and anti–phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes.
Prospective cohort study.
One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes.
Rituximab.
Complete (proteinuria<0.3g/24h) or partial (proteinuria≥0.3g/24h and<3.0g/24h with>50% reduction vs basal) NS remission.
Univariable and multivariable Cox regression analyses.
All patients had anti-CysR antibodies; 62 (54.9%) were multidomain recognizers. Anti-PLA2R1 and anti-CysR antibody titers were strongly correlated at baseline (P<0.001, r=0.934), 6 months (P<0.001, r=0.964), and 12 months (P<0.001, r=0.944). During a median follow-up of 37.1 (IQR, 20.3-56.9) months, 71 patients (62.8%) achieved either complete or partial remission of their NS. Lower baseline anti-PLA2R1 (HR, 0.997 [95% CI, 0.996-0.999], P=0.002) and anti-CysR [HR, 0.996 [95% CI, 0.993-0.998], P=0.001) titers were associated with a higher probability of remission, along with female sex, lower proteinuria, and lower serum creatinine levels (P<0.05 for all comparisons). Anti-CTLD antibodies were not associated with outcomes. At 6 and 12 months, compared to baseline, anti-PLA2R1 and anti-CysR antibody titers decreased more in patients progressing to partial or complete remission than in those without remission (P<0.05 for all comparisons).
Observational design.
In PLA2R1-related MN, anti-PLA2R1 and anti-CysR antibodies similarly predict rituximab efficacy independent of PLA2R1 domain recognition. The choice between these tests should be dictated by feasibility and costs. Evaluating anti-CTLD antibodies appears unnecessary.
Primary membranous nephropathy (MN), a leading cause of nephrotic syndrome (NS) in adults, is an autoimmune disease caused by autoantibodies binding to the podocyte antigen phospholipase A2 receptor 1 (PLA2R1). We assessed whether the effects of anti-CD20 cytolytic therapy with the monoclonal antibody rituximab are associated with detection rates and levels of anti-PLA2R1 antibodies and antibodies against PLA2R1 domains such as cysteine-rich (CysR), and C-type lectin 1, 7, and 8 (CTLD1, 7, and 8), in patients with PLA2R1-related MN and persistent NS. The probability of rituximab-induced complete or partial NS remission was associated with baseline anti-PLA2R1 and anti-CysR antibody titers, but not with anti-CTLD1, 7 and 8 antibodies or multidomain recognition. Integrated evaluation of anti-PLA2R1 or anti-CysR antibodies with proteinuria and kidney function may play a role in monitoring the effects of rituximab in patients with PLA2R1-related NS and MN.
[Display omitted]]]></abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38151224</pmid><doi>10.1053/j.ajkd.2023.10.013</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-6386 |
| ispartof | American journal of kidney diseases, 2024-05, Vol.83 (5), p.588-600.e1 |
| issn | 0272-6386 1523-6838 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2907196579 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Autoantibodies - blood Autoantibodies - immunology Cohort Studies CysR Cysteine domain recognition Female Glomerulonephritis, Membranous - drug therapy Glomerulonephritis, Membranous - immunology Humans Immunologic Factors - therapeutic use Male membranous nephropathy Middle Aged nephrotic syndrome PLA2R1 Prospective Studies Proteinuria - drug therapy Receptors, Phospholipase A2 - immunology rituximab Rituximab - therapeutic use sex Treatment Outcome |
| title | Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%93Phospholipase%20A2%20Receptor%201%20and%20Anti%E2%80%93Cysteine%20Rich%20Antibodies,%20Domain%20Recognition%20and%20Rituximab%20Efficacy%20in%20Membranous%20Nephropathy:%20A%20Prospective%20Cohort%20Study&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Ruggenenti,%20Piero&rft.date=2024-05&rft.volume=83&rft.issue=5&rft.spage=588&rft.epage=600.e1&rft.pages=588-600.e1&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2023.10.013&rft_dat=%3Cproquest_cross%3E2907196579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2907196579&rft_id=info:pmid/38151224&rft_els_id=S0272638623009939&rfr_iscdi=true |